Immucell (ICCC) Common Equity (2016 - 2025)
Historic Common Equity for Immucell (ICCC) over the last 16 years, with Q3 2025 value amounting to $29.8 million.
- Immucell's Common Equity rose 1283.21% to $29.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $29.8 million, marking a year-over-year increase of 1283.21%. This contributed to the annual value of $27.5 million for FY2024, which is 1010.32% up from last year.
- As of Q3 2025, Immucell's Common Equity stood at $29.8 million, which was up 1283.21% from $29.9 million recorded in Q2 2025.
- In the past 5 years, Immucell's Common Equity registered a high of $33.2 million during Q1 2022, and its lowest value of $23.5 million during Q2 2024.
- Moreover, its 5-year median value for Common Equity was $29.0 million (2025), whereas its average is $28.9 million.
- Per our database at Business Quant, Immucell's Common Equity crashed by 1866.34% in 2023 and then skyrocketed by 2733.68% in 2025.
- Quarter analysis of 5 years shows Immucell's Common Equity stood at $32.6 million in 2021, then fell by 6.74% to $30.4 million in 2022, then dropped by 17.73% to $25.0 million in 2023, then rose by 10.1% to $27.5 million in 2024, then increased by 8.3% to $29.8 million in 2025.
- Its Common Equity stands at $29.8 million for Q3 2025, versus $29.9 million for Q2 2025 and $29.0 million for Q1 2025.